Effectiveness in preventing post-biopsy bleeding complication in CKD patients comparing between transdermal estrogen and desmopressin Uremic bleeding, kidney biopsy, Estrogen, Transdermal estrogen, DDAVP, desmopressin
Conditions
Interventions
transdermal estrogen
50 mcg of estradiol / 24 hours
Climara,0.4 mcg/kg Intravenous desmopressin
Experimental Drug,Active Comparator Drug
Transdermal estrogen,Desmopressin
Sponsors
Kinh Chulalongkorn memorial hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were patients undergoing ultrasound-guided kidney biopsy who were aged above 18 years and estimated glomerular filtration rate (GFR) less than 60 mL/min (calculated using CKD-EPI) with blood pressure less than 140/90 mmHg and hemoglobin more or equal 10 g/dL and normal coagulation parameter (PT and PTT)
Exclusion criteria
Exclusion criteria: patients with history of venous thromboembolism (deep vein thrombosis or pulmonary embolism), history of breast cancer and endometrial cancer, abnormal vaginal bleeding, liver disease and/or history of coronary disease or cerebrovascular disease in previous 1 month before kidney biopsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postbiopsy bleeding events within 24 hours incidence | — |
Secondary
| Measure | Time frame |
|---|---|
| hematoma size within 24 hours cm2,Hemoglobin level changes within 24 h Hemoglobin level,major bleeding events within 24 h incidence,Platelet function within 24 h PFA-200 | — |
Countries
Thailand
Contacts
Public ContactAschariya Wipattanakitcharoen
King chulalongkorn memorial hospital
Outcome results
None listed